Mark Emalfarb
Vermogen: 4 M $ op 31-05-2026
Vermogen: 4 M $ op 31-05-2026
Mark A. Emalfarb is the founder of Dyadic International, Inc., founded in 1979, holding the title of Chief Executive Officer & Director.
Current jobs include Chairman & Chief Executive Officer at Dyadic International (USA), Inc., and Director at Biotechnology Development for Industry in Pharmaceuticals SLU since 2017.
Education includes an undergraduate degree from the University of Iowa, conferred in 1977.
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
| 24-04-2026 | 4.832.667 ( 13,26% ) | 4 M $ | 31-05-2026 |
| Bedrijven | Functie | Begin |
|---|---|---|
| DYADIC INTERNATIONAL, INC. | Oprichter | 01-01-1979 |
Dyadic International (USA), Inc.
Dyadic International (USA), Inc. BiotechnologyHealth Technology Researches and manufactures genes | Algemeen Directeur | 05-10-2011 |
Biotechnology Development for Industry in Pharmaceuticals SLU
Biotechnology Development for Industry in Pharmaceuticals SLU Miscellaneous Commercial ServicesCommercial Services Operates as an biotechnology company which produces recombinant proteins | Directeur/Bestuurslid | 13-09-2017 |
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
| Bedrijven in privébezit | 4 |
|---|---|
Dyadic International, Inc.
Dyadic International, Inc. Medical/Nursing ServicesHealth Services Manufactures genes and other biological products | Health Services |
University of Iowa
University of Iowa Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Dyadic International (USA), Inc.
Dyadic International (USA), Inc. BiotechnologyHealth Technology Researches and manufactures genes | Health Technology |
Biotechnology Development for Industry in Pharmaceuticals SLU
Biotechnology Development for Industry in Pharmaceuticals SLU Miscellaneous Commercial ServicesCommercial Services Operates as an biotechnology company which produces recombinant proteins | Commercial Services |
Kies jouw editie
Alle financiële informatie op nationaal niveau